BiomXPHGE
PHGE
About: BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Employees: 57
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
20% more funds holding
Funds holding: 15 [Q3] → 18 (+3) [Q4]
4.73% more ownership
Funds ownership: 50.59% [Q3] → 55.32% (+4.73%) [Q4]
21% less capital invested
Capital invested by funds: $9.24M [Q3] → $7.32M (-$1.92M) [Q4]
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$21
3,348%
upside
Avg. target
$21
3,348%
upside
High target
$21
3,348%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 3,348%upside $21 | Buy Reiterated | 4 Apr 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
4 weeks ago
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification.
Neutral
GlobeNewsWire
1 month ago
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results
Neutral
GlobeNewsWire
1 month ago
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided program and business updates.
Neutral
GlobeNewsWire
1 month ago
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.
Neutral
Seeking Alpha
5 months ago
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Sara Nik – H.C. Wainwright Operator Greetings, and welcome to the BiomX Third Quarter 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
5 months ago
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
Neutral
GlobeNewsWire
5 months ago
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
Neutral
GlobeNewsWire
6 months ago
BiomX Announces a Mandatory Unit Separation
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.
Positive
Zacks Investment Research
7 months ago
BiomX Stock Gains From Favorable Study Data Presentation on BX004
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.
Charts implemented using Lightweight Charts™